The Absolute Essentials Of Manufacturability: Ensuring Process Continuity From Research To Commercialization

By Maik W. Jornitz, principal consultant, BioProcess Resources LLC

Introduction

Over the past two decades, the life-sciences industry has undergone a significant transformation in how therapies are discovered, developed, and ultimately produced. Breakthrough modalities — including lipid nanoparticles (LNPs), gene therapies, messenger-RNA (mRNA)-based vaccines, and targeted nanocarriers — have radically redefined the boundaries of modern medicine. These new approaches promise potent, often personalized treatments for previously intractable diseases. However, amid this wave of innovation lies a persistent and often underestimated challenge: manufacturability of the process itself.

Manufacturability is far more than a mere downstream engineering concern or a production line headache; it is an essential design parameter that must be embedded at the research stage. Too often, early-stage development focuses almost exclusively on proof-of-concept data (e.g., demonstration of biological activity, particle formation, in vitro efficacy) or analytical success (e.g., establishing assays, characterizing size, encapsulation, release) — while neglecting whether the process engineered at bench scale will scale reproducibly and efficiently to pilot, clinical, and commercial manufacturing. When this misalignment occurs, the transition from bench to pilot scale – and ultimately to clinical/commercial manufacturing – is fraught with risk, delay, substantially higher cost, and regulatory non-compliance.

Regulators around the world (such as the Food and Drug Administration (FDA) in the US, the European Medicines Agency (EMA) in Europe, and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)) have increasingly emphasized the importance of process understanding, scalability and application of quality-by-design (QbD) principles. For clinical programs built on weak process foundations, regulatory scrutiny is now more acute than ever. The era of “develop now, fix later on the manufacturing side” is rapidly fading. The modern expectation is clear: a therapeutic must not only be scientifically sound — it must also be manufacturable.

This paper stresses that manufacturability is not an afterthought; it is a foundational pillar of successful translation from research through to commercialization and begins with the need of process equipment scalability for example. By embedding manufacturability early — through process design, equipment selection, scale-up planning, control strategy development, and regulatory alignment — organizations can dramatically reduce risk, accelerate timelines, and optimize cost‐allocations and efficiencies.

Defining Manufacturability in the Modern Context

To discuss manufacturability meaningfully, it is crucial to define it within the context of modern biopharmaceutical / nanomedicine development. Manufacturability can be defined as:

“The inherent capability of a process to produce a consistent, high-quality product that can be scaled efficiently and reproducibly from research to full commercial production.”

This definition emphasizes several key dimensions:

  • Process design: The structure of steps, unit operations, materials, mixing, filtration, purification, fill/finish.
  • Equipment selection: Choosing equipment that not only works at bench scale, but can be scaled, replicated, qualified, and controlled at pilot and commercial scales. This fact is a most common oversight.
  • Material flow and handling: Raw materials, intermediates, reagents, disposables, and consumables must all align with scalable manufacturing and facility designs, which becomes a prevalent focus when applying it to the FDA PreCheck initative.
  • Automation and control strategy: The ability to monitor, control and record process parameters in a robust and reproducible way.
  • Scalability and reproducibility: Ensuring that what works at 10 mL or 1 L works at 100 L or 1,000 L with minimal or no redesign or variation.
  • Regulatory and GMP compliance: The process must be capable of meeting Good Manufacturing Practice (GMP) expectations, regulatory filings, validation and life-cycle control.

In the context of nanoparticle or lipid-nanoparticle-based systems (for example, LNPs for mRNA delivery), manufacturability involves specific technical realities:

  • Reproducible mixing dynamics that define particle size, polydispersity index (PDI), encapsulation efficiency and stability.
  • Linear scalability of process parameters: ensuring that hydrodynamic and shear environment remain constant across scale.
  • Ease of validation and integration of Process Analytical Technology (PAT) for real-time process monitoring.
  • Compliance with GMP expectations and regulatory frameworks around advanced modalities.

At its core, manufacturability is about continuity and control — designing a process that behaves predictably whether it is producing milliliters, liters or thousands of liters of material. Without this continuity, what works in the lab may fail in manufacturing, costing time, money, market share and regulatory success.

The Cost of Ignoring Manufacturability Early

When manufacturability is ignored or treated as an afterthought, the consequences echo through the development lifecycle. Many R&D laboratories focus on proof-of-concept using small-scale, non-scalable instruments — such as custom microfluidic chips, syringe pumps, or manual bench rigs. These may produce excellent scientific data but fail to reproduce the same conditions at pilot or production scale.

The consequences of this misalignment include:

  • Process redesign: Once scaling limitations become evident, the process often needs to be re-engineered from scratch, rendering much of the earlier development work redundant.
  • Regulatory delays: Regulatory bodies expect the manufacturing and clinical materials to originate from a consistent, validated process. If the process changes significantly (due to scale-up failure), comparability and validation studies are required, delaying filings.
  • Increased costs: Redoing process development, additional bridging studies, waste of materials and time can double or triple the cost of the Chemistry, Manufacturing and Controls (CMC) package.
  • Loss of time-to-market advantage: In highly competitive therapeutic fields, a six-month delay may translate into tens of millions of dollars in lost revenue, market share shift, or competitor advantage.

By contrast, when manufacturability is designed into the earliest stages — by selecting linearly scalable mixing technologies, embedding automation and data-rich controls, establishing quality-by-design frameworks — the program is positioned for smoother transitions, faster validation and better regulatory confidence. Studies show that implementation of QbD, which by definition informs manufacturability, can reduce development time by up to 40%. Further, focusing on critical quality attributes and process parameters early reduces batch failures and rework significantly.

Hence ignoring manufacturability is not simply a technical oversight, it is an economic and strategic liability.

The Regulatory Lens: From QbD to Advanced Manufacturing

Regulatory agencies worldwide have become increasingly assertive regarding the manufacturability of new therapeutic modalities. Key guidance documents such as ICH Q8: Pharmaceutical Development, ICH Q9: Quality Risk Management, and ICH Q12: Lifecycle Management all reinforce the expectation that developers demonstrate deep process understanding.

The FDA’s Office of Pharmaceutical Quality (OPQ) and Center for Biologics Evaluation and Research (CBER) have repeatedly emphasized that clinical programs built on poorly defined or non-scalable processes will face regulatory challenge. In practice, this means that if a developer cannot demonstrate how a research-scale process translates to a GMP-manufacturable process, regulators may:

  • Request additional comparability studies, delaying clinical entry.
  • Reject the CMC section of an Investigational New Drug (IND) application for lack of control strategy or inadequate process description.
  • Place clinical holds pending resolution of manufacturability gaps.

Additionally, the FDA’s Advanced Manufacturing Technology (AMT) program encourages adoption of scalable, continuous and well-controlled technologies that inherently support manufacturability. Technologies such as turbulent-jet mixing (which can demonstrate linear scalability from microliter to liter volumes) are increasingly viewed as aligned with regulatory expectations. Thus, the regulatory climate is no longer passive about manufacturing — regulators expect early-stage developers to adopt a forward-looking, manufacturable approach from the very first experiment. This elevates the importance of manufacturability from internal engineering optimization to a regulatory requirement.

The Critical Role of Equipment Design and Scalability

At the heart of manufacturability lies equipment design. The equipment selected defines not only what can be made but also how consistently it can be made across scales. In the domain of nanoparticles and LNP formulations, the mixing dynamics are a critical determinant of product attributes such as particle size distribution, polydispersity, encapsulation efficiency, and downstream stability.

The challenge arises when lab-scale systems use hydrodynamic regimes that cannot be replicated at larger scales. For example, microfluidic chips may produce excellent small-scale data, but the Reynolds numbers, shear rates, residence times and mixing energies often cannot be scaled linearly. When scale‐up moves into higher volumes and flow rates, the fluid dynamics change and with them, the product attributes can shift unpredictably. Furthermore, scaling out does not equal scaling up. A parallel scaling means that a multitude of systems are interconnected create another variability of the process as well as unpredictable fluid pathways and hold-up volumes. One cannot just focus on the scale-up approach but also review a scaling out process which can be as detrimentally influenced.

Technologies engineered for linear scalability — such as turbulent-jet mixing systems — address this by maintaining consistent flow regimes, shear distributions, mixing times and residence times across scale. In other words, the geometry, energy input and mixing environment are designed so that what happens at 10 mL happens the same way at 100 L.

Key aspects of scalable equipment design include:

  • Geometric similarity — ensuring the same flow path and shear distribution across scales.
  • Constant mixing energy per volume — preserving the hydrodynamic balance.
  • Data traceability — capturing all process variables (flow rate, pressure, temperature) so that the process can be controlled and transferred digitally.
  • Single-use adaptability — allowing flexibility, reducing contamination risk, and simplifying scale-up logistics.

If any of these design features are missing, the risk of divergence between R&D outcomes and production scale increases dramatically. Therefore, equipment design and scale‐up planning must not be treated as a later step, they must be embedded early as part of the process design.

Integrating Quality by Design (QbD) and Process Analytical Technology (PAT)

Manufacturability is most robust when coupled with a formal Quality by Design (QbD) framework and real-time Process Analytical Technology (PAT) integration. QbD is a systematic and science-based development approach that begins with predefined objectives and emphasizes deep understanding of both product and process. Key elements of QbD include: defining the Quality Target Product Profile (QTPP), identifying Critical Quality Attributes (CQAs), identifying Critical Process Parameters (CPPs), establishing a design space and then implementing a control strategy.

In the context of nanoparticle/LNP processing, CPPs might include:

  • Mixing flow ratio (lipid phase / aqueous phase)
  • Total flow rate or throughput
  • Residence time and temperature
  • Shear post-processing (e.g., extrusion, homogenization)
  • Filtration or diafiltration parameters
  • Encapsulation efficiency, payload leakage, size/polydispersity

The CQAs might include:

  • Particle size distribution (mean and PDI)
  • Encapsulation efficiency
  • Payload integrity
  • Endotoxin/sterility status (for biologics)
  • Residual solvent
  • Stability
  • Deliverable dose

PAT tools — such as inline particle-size analyzers, UV/Vis absorption monitoring, pressure‐flow sensors, in-line NIR or Raman spectroscopy — enable real-time process monitoring and allow developers to understand how process parameters influence product attributes. This enables data-driven decision-making, real-time adjustment and predictive control rather than reactive troubleshooting. The integration of PAT into scalable platforms transforms manufacturability from manual craft into robust, controlled science.

Implementation of QbD and PAT from the earliest stages ensures that manufacturability becomes a natural outcome rather than an afterthought. This alignment significantly reduces the number of experimental iterations required to reach a validated process. Indeed, one review concluded that QbD implementation reduces batch failures by about 40 %.

Mind the Gap: From Research to GMP

One of the most critical junctures in product development is the transition from research / discovery to GMP production and this is exactly where manufacturability (or the lack of it) becomes fully exposed. A research process built on non-scalable tools often suffers from multiple challenges:

  • Material incompatibility: Research may use non-GMP materials, lab-scale reagents, small-scale consumables, or non-qualified disposables that cannot be transferred to GMP.
  • Lack of digital records: Manual data collection in R&D does not provide the traceability, metadata or electronic batch records required for GMP.
  • Inconsistent results on scale-up: Because fluid dynamics, heat transfers, mixing regimes and residence times shift with scale, unexpected variability emerges.
  • Inefficient technology transfer: When process, equipment or data aren’t standardized or well-documented, hand-off to a contract manufacturing organization (CMO) or scaling facility becomes complicated.

By contrast, a scalable, manufacturable platform (i.e., one whose benchtop equipment, control strategy, mixing regime and data capture align with the pilot/production scale) significantly mitigates these risks. For example, if a process developed on a benchtop discovery system uses the same mixing geometry, same flow regime, same shear conditions and the same operator control logic as the GMP manufacturing equipment, then the technology transfer is practically seamless. The process data, parameter ranges and control strategy remain applicable across scale. Material-, equipment- and software-incompatibilities are minimized. This continuity supports regulatory filings: when IND, IMPD or commercial submission data are based on the same process backbone from small scale to manufacture, the regulatory reviewer sees continuity, traceability and control.

Manufacturability and the Economics of Development

Manufacturability is not merely a technical or regulatory consideration; it is also a financial strategy. In an era of increased cost-pressure on the biopharmaceutical industry (long development cycles, high attrition, shrinking margins), the ability to scale efficiently and reliably becomes a competitive advantage.

Programs that integrate manufacturability early enjoy tangible economic benefits:

  • Reduced development time: Fewer redesigns and process changes shorten CMC timelines by up to ~40%.
  • Lower cost of goods (COGs): Scalable, automated systems minimize manual labor, reduce material losses, lower scrap, and reduce overhead.
  • Accelerated time-to-market: Manufacturable processes enable earlier GMP readiness and commercial launch, capturing market value sooner.
  • Investor confidence: Investors increasingly assess manufacturability as a proxy for long-term viability. A process that cannot be manufactured reliably is not an asset, it’s a risk.

Hence, manufacturability becomes a strategic differentiator: those companies that design for scale and control from Day 1 have lower risk, lower cost, faster launch—and higher potential return. Conversely, those that treat scale-up as a “phase 2 problem” put themselves at a strategic disadvantage.

Building a Culture of Manufacturability

Embedding manufacturability into a company’s DNA requires more than a good process design; it requires a cultural shift. Manufacturability must be treated as a cross-functional discipline that spans R&D, engineering, quality, regulatory and operations. Key elements of this culture include:

  • Early collaboration between research and manufacturing teams: From the earliest formulation studies, manufacturing engineers should be involved to ensure that the experimental design aligns with scalable equipment, validated materials, control strategy and data capture.
  • Modular, automated, and data-rich platforms that bridge discovery and GMP: Using equipment that can scale, capture data and align with manufacturing environments ensures continuity.
  • Continuous training on regulatory expectations and scalability principles: As regulatory expectations evolve (e.g., ICH Q8/9/10/12), teams must stay current.
  • Integration of digital tools for process data management and simulation-based design: Digital twins, simulation of mixing/shear/flow regimes, data analytics and real-time monitoring help design for scale long before the first liter is produced.
  • Lifecycle mindset: Process development is not finished at scale-up. Implementing QbD means establishing control strategies, monitoring, continuous improvement and life-cycle management (per ICH Q12) across commercial life.

By cultivating this culture, manufacturability becomes part of the design philosophy — not a corrective measure that is applied when things go wrong.

Conclusion

As the pharmaceutical and biotechnology industry continues its evolution toward complex biologics, nanomedicines, precision therapies and personalized modalities, manufacturability will define the next era of success. It is the critical link between discovery and delivery — the difference between a promising concept and a viable therapeutic.

Ignoring manufacturability in early research is no longer an option. Regulatory agencies, investors, and patients alike demand that innovation be grounded in control, reproducibility and scalability. Processes must be designed not only for scientific success, but for industrial feasibility and long-term reliability.

In practical terms, the most forward-thinking organizations are already embracing this shift. They are selecting scalable technologies, designing QbD-based development frameworks, constructing control strategies and fostering collaboration between research and manufacturing disciplines. By doing so, they are ensuring that their innovations are not only novel, but manufacturable, compliant, profitable and ready for the patient.

References

  • Anliker S, Mercer J, Schofield T, “Quality by Design for Biotechnology Products — Part 1”, BioPharm International, Nov 1 2009.
  • “Pharmaceutical Quality by Design: Product and Process Development, Understanding and Control”, J. Pharm. Sci., (2008) 97:8.
  • “Aspects and Implementation of Pharmaceutical Quality by Design from Conceptual Frameworks to Industrial Applications”, PubMed, (2025).
  • “Quality by Design (QbD) in Pharmaceutical Industry: Tools, Perspectives and Challenges”, PharmaTutor.
  • “Rethinking Pharmaceutical Industry with Quality by Design: Application in Research, Development, Manufacturing, and Quality Assurance”, PharmaExcipients, (2025).
  • “QbD Helps Evaluate Excipient Variability”, Pharmaceutical Technology, (2025).
  • “Roadmap for implementation of QbD for biotechnology products”, PubMed, (2010).
  • “Pharmaceutical Quality by Design – Beckman White Paper”.
  • “An industrial case study: QbD to accelerate time-to-market of a drug product”, AAPS Open (2021).